McDonough, Founder and CEO of Agio
, this information lets them know what's working and what isn't.
Latest news and deals relating to the Agios
The United States Food and Drug Administration has granted orphan drug designation to United States-based Agios
Pharmaceuticals' AG-348, intended to treat pyruvate kinase deficiency, a rare form of haemolytic anaemia, it was reported yesterday.
Tumors carrying IDH mutations are known to produce high levels of 2-HG, as shown originally by Agios
scientists in Nature in 2009.
Contract notice: Supporting work at ses agios
Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the fields of cancer metabolism and rare metabolic genetic diseases, today announced that David Schenkein, M.
Pharmaceuticals and The University of Pennsylvania (Penn) have inked a licensing agreement for new intellectual property suitable for use to develop diagnostic products to identify certain cancer metabolisms.
18 November 2011 - US Agios
Pharmaceuticals said yesterday it had raised USD78m (EUR57.
Taken together, our talks illustrate the innovative research capabilities and the insights into novel targets in metabolism that make Agios
a leader in the field.
M2 PHARMA-October 6, 2011-Celgene, Agios
extend cancer metabolism partnership by one year(C)2011 M2 COMMUNICATIONS
Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the fields of cancer metabolism and rare metabolic genetic diseases, announced today a recent publication that highlights the discovery of the first potent inhibitors of mutant isocitrate dehydrogenase (IDH) that lower tumor 2-HG in vivo.